NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT00617708 2022-02-08
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00503685 2018-06-06
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Eli Lilly and Company
Phase 2 Completed
NCT01008566 2016-05-12
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00831844 2015-03-30
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00639509 2014-05-23
IMC-A12 in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed